Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Skin cancer, neuroendocrine carcinoma (Merkel cell)
Country:  U.S.A.
Trial Type:  Treatment
Results 1-17 of 17 for your search:
Start Over
Embolization Therapy with or without Chemotherapy in Controlling Liver Metastases in Patients with Neuroendocrine Tumor Metastases to the Liver That Cannot Be Removed by Surgery
Status: Active
Phase: Phase III
Type: Diagnostic, Treatment
Age: 18 and over
Trial IDs: UPCC01215, NCI-2016-00610, NCT02724540
A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: BBI608-201, NCI-2014-01566, NCT01325441
An Investigational Immuno-therapy Study to Investigate the Safety and Effectiveness of Nivolumab, and Nivolumab Combination Therapy in Virus-associated Tumors
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CA209-358, NCI-2015-01356, 2015-000230-29, NCT02488759
Localized Radiation Therapy or Recombinant Interferon Beta and Avelumab with or without Cellular Adoptive Immunotherapy in Treating Patients with Metastatic Merkel Cell Carcinoma
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 9245, NCI-2014-02462, FHCRC 9245, NCT02584829
Sapanisertib in Treating Patients with Recurrent or Metastatic Merkel Cell Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 15-223, NCI-2016-00695, NCT02514824
Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: Any age
Trial IDs: SCRX001-006, NCI-2016-01071, NCT02709889
PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung Cancers
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: PEN-221-001, NCI-2017-00043, NCT02936323
Cabozantinib-S-Malate in Treating Patients with Recurrent or Metastatic Merkel Cell Carcinoma
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 13-490, NCI-2014-00941, NCT02036476
Avelumab in Subjects With Merkel Cell Carcinoma (JAVELIN Merkel 200)
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 100070-003, NCI-2014-01995, 2014-000445-79, NCT02155647
QUILT-3.009: Study of aNK Infusions in Combination With ALT-803 in Patients With Stage III (IIIB) or Stage (IV) Merkel Cell Carcinoma (MCC)
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: MCC-001, NCI-2015-01343, QUILT-3.009, NCT02465957
Ramucirumab and Somatostatin Analog Therapy in Treating Patients with Locally Advanced or Metastatic Carcinoid Tumor That Cannot Be Removed by Surgery
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 16-072, NCI-2016-00941, NCT02795858
Nivolumab and Ipilimumab in Treating Patients with Rare Tumors
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: S1609, NCI-2016-01041, NCT02834013
RRx-001 in Small, Non-small Cell Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: RRx001-211-01, NCI-2016-01889, NCT02489903
Nivolumab and Ipilimumab with or without Stereotactic Body Radiation Therapy in Treating Patients with Recurrent or Stage IV Merkel Cell Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: MCC-18786, NCI-2017-00427, NCT03071406
Atezolizumab and Bevacizumab in Treating Patients with Rare Solid Tumors
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 2016-0861, NCI-2017-00501, NCT03074513
Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: TTI-621-02, NCI-2016-01486, NCT02890368
Start Over